ClinicalTrials.gg
Not yet recruitingNCT07463716Updated Mar 11, 2026

The Effect of Home and Hospital Mask Designs on Respiratory Variables in Healthy Volunteers

An interventional study of Non-invasive ventilation (NIV) in Healthy Volunteers, sponsored by Fisher and Paykel Healthcare. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-11.

Sponsored by Fisher and Paykel Healthcare · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this randomized cross-over study is to investigate whether the design of non-invasive ventilation (NIV) mask impacts respiratory variables in healthy volunteers on NIV therapy. The main questions it aims to answer are:

  • To assess if mask design impacts the ventilatory ratio in healthy volunteers.
  • To assess if mask design impacts transcutaneous CO2, respiratory rate, and tidal volume in healthy volunteers.

Participants will attend five study visits:

  • Visit 1. Participants will be fitted to use non-invasive ventilation briefly to acclimatize them to using the therapy.
  • Visit 2. Participants will receive NIV with one of four masks. They will be asked to breathe through their mouth or through their nose, with a break from NIV in between the two sessions of NIV.
  • Visits 3-5. Participants will receive NIV with one of the other three masks, repeating Visit 2.
Read the detailed description

The study compares breathing with four different NIV masks, the interventional mask and three conventional NIV masks. Participants will be monitored by transcutaneous carbon dioxide, heart rate, oxygen, and respiratory rate monitors.

Participants will attend five study visits:

  • Visit 1. Participants will be fitted to use NIV briefly to acclimatize them to using the therapy and ensure the four study masks fit. Participants that fit the masks and tolerate NIV well will be invited to attend four further visits.
  • Visit 2. Participants will be randomized as to which order they receive the masks, and which order they conduct mouth breathing and nose breathing. Baseline readings of normal unsupported breathing will be taken prior to going on NIV. Participants will the receive NIV with one of four masks for ten minutes and will be instructed to either breathe through their mouth or their nose. There will then be a break from NIV of at least ten minutes until baseline values of respiratory parameters have returned. Then there will be a second ten-minute period of NIV when the participant will be instructed to breathe through the other way through the nose or mouth. Once NIV therapy has been removed the participant will remain attached to the study monitoring equipment until respiratory parameters have returned to normal.
  • Visits 3-5 are a repeat of Visit 2 with the other study masks. The study is then complete.
02

Conditions studied

  • Healthy Volunteers

Keywords

  • Noninvasive ventilation
  • Pulmonary
03

In context

Lead sponsor

Fisher and Paykel Healthcare is the lead sponsor of 86 studies on the registry; 16 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 10 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years or over
  • Able to give

Exclusion criteria

Exclusion Criteria:

  • Unable to tolerate non-invasive ventilation (NIV)
  • Unable to adequately fit an NIV mask
  • Claustrophobia while using NIV
  • Symptoms of cold or flu (including COVID-19) in previous twenty-four hours
  • Chronic Rhinitis or self-reported history of upper airway obstruction
  • Pneumothorax or history of previous pneumothorax
  • Employee in the NIV team at Fisher \& Paykel Healthcare
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    NIV using Mask A, with mouth-open

    Mask A is the investigational mask

    Device: Non-invasive ventilation (NIV)

  • Experimental
    NIV using Mask A, with mouth-closed

    Mask A is the investigational mask

    Device: Non-invasive ventilation (NIV)

  • Active comparator
    NIV using Mask B, with mouth-open

    Mask B is a comparator mask

    Device: Non-invasive ventilation (NIV)

  • Active comparator
    NIV using Mask B, with mouth-closed

    Mask B is a comparator mask

    Device: Non-invasive ventilation (NIV)

  • Active comparator
    NIV using Mask C, with mouth-open

    Mask C is a comparator mask

    Device: Non-invasive ventilation (NIV)

  • Active comparator
    NIV using Mask C, with mouth-closed

    Mask C is a comparator mask

    Device: Non-invasive ventilation (NIV)

  • Active comparator
    NIV using Mask D, with mouth-open

    Mask D is a comparator mask

    Device: Non-invasive ventilation (NIV)

  • Active comparator
    NIV using Mask D, with mouth-closed

    Mask D is a comparator mask

    Device: Non-invasive ventilation (NIV)

Interventions

  • DeviceNon-invasive ventilation (NIV)

    Delivery of positive airway pressure to the lungs via an interface, such as a mask

06

What researchers measure

Primary outcomes

  1. Change in ventilatory ratio

    To assess if mask design can reduce ventilatory ration in healthy volunteers

    Time frame: 15 minutes

Secondary outcomes

  1. Change in transcutaneous carbon dioxide (CO2)

    To assess if mask design can reduce transcutaneous CO2 in healthy volunteers

    Time frame: 15 minutes

  2. Change in respiratory rate

    To assess if mask design can reduce respiratory rate in healthy volunteers

    Time frame: 15 minutes

  3. Change in tidal volume

    To assess if mask design can reduce tidal volume in healthy volunteers

    Time frame: 15 minutes

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — All data to be deidentified

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2026; primary completion for May 2026, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2026
First posted
Mar 11, 2026
StartEst.
Mar 2026
Primary completionEst.
May 2026
CompletionEst.
Jun 2026
Last update
Mar 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07463716
Responsible party
Sponsor
First posted
Mar 11, 2026
Start date
Mar 2026 (estimated)
Primary completion
May 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Mar 11, 2026

Study contacts

Olivia Kennington
Contact
olivia.kennington@fphcare.co.nz
+64(09)5740100 ext. 5425
William Good, Medical degree
principal investigator · Middlemore Hospital, New Zealand

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion